Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
188M
-
Shares change
-
-4.31M
-
Total reported value, excl. options
-
$401M
-
Value change
-
-$13M
-
Put/Call ratio
-
0.7
-
Number of buys
-
77
-
Number of sells
-
-59
-
Price
-
$2.13
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2024
190 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q4 2024.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 188M shares
of 226M outstanding shares and own 83.28% of the company stock.
Largest 10 shareholders include FMR LLC (23.8M shares), Pfizer Inc (22M shares), TPG GP A, LLC (18.7M shares), BlackRock, Inc. (18.1M shares), Lynx1 Capital Management LP (10.9M shares), VANGUARD GROUP INC (8M shares), STATE STREET CORP (7.25M shares), Capital World Investors (6.9M shares), CITADEL ADVISORS LLC (5.35M shares), and PRIMECAP MANAGEMENT CO/CA/ (4.93M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.